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Background: Mechanical thrombectomy (MT) is a new evidence-based treatment option for large vessel occlusion in
the anterior brain circulation. Using comprehensive administrative data from Germany, we analysed the nationwide
development of intravenous thrombolysis (IVT) and MT in Germany between 2010 and 2016.
Methods: We considered all documented cases (n = 1,515,634) with a main diagnosis of the ICD-10-GM code I63
(ischemic stroke) and identified specific stroke recanalization therapy by using the corresponding Operating and
Procedure Key for systemic thrombolysis and mechanical thrombectomy out of the DRG statistics. Regional
analyses are based on data from the 413 German administrative districts and cities and the obligatory quality
reports of all hospitals. We distinguished between rates of MT related to place of residence of patients and place
of treatment.
Results: Coded ischemic strokes increased by 10.2% from 2010 (n= 206.688) to 2016 (n = 227.687). The rate of IVT
increased from 8.9% in 2010 to 14.9% in 2016 and the rate of MT increased from 0.8% in 2010 to 4.7% in 2016 with a
strong increase in 2015 and 2016. There was a high regional variability of MT according to place of residence of patients
between 0 and 11.2% in 2016 with significant lower treatment rates in rural compared to urban areas (3.8 vs 5.4%). Mean
age of patients treated with MT increased from 67.8 years in 2010 to 73.3 years in 2016 and almost reached the mean age
of IVT treated patients (74.4 years). The number of hospitals coding MT increased from 91 to 193 from 2010 to 2016, but
80% of all MT procedures were performed in neurointerventional centers with ≥50 procedures/year in 2016.
Conclusions: The rate of IVT in patients with acute ischemic stroke in Germany continues to rise and has reached 14.9%
nationwide. The increase of MT is even more pronounced and was triggered by the evidence after publication of the MT
randomized trials. There is still a high regional variability with significant lower MT rates in rural areas.
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Stroke accounts for the largest proportion of disability-
adjusted life year loss and two-thirds of deaths among
all neurological disorders in the Global Burden of Dis-
ease Study 2015 [1]. In 2015, five randomized trials
showed that mechanical thrombectomy (MT) with stent
retrievers is effective and safe in patients with large* Correspondence: Eyding@web.de
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if performed within 6 h after stroke onset on top of
intravenous thrombolysis (IVT) alone [5–9]. MT has be-
come the third evidence-based column of acute stroke
therapy besides stroke unit treatment and IVT with re-
combinant tissue plasminogen activator (rt-PA) [10–13].
It is estimated that between 7 and 15% of all stroke
patients could be candidates for MT [14–16].
Whilst most stroke patients in high income countries
have access to stroke unit care, the uptake of IVT was rela-
tively slow. Given these limitations of care, the implemen-
tation and access to MT may be even more difficult tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Weber et al. Neurological Research and Practice             (2019) 1:4 Page 2 of 9achieve. Based on administrative data from all acute care
hospitals in all 413 cities/regions of Germany, we analysed
the nationwide evolution of IVT and MT in hospitalized
acute stroke patients from 2010 to 2016 with a special
focus on places of residence and places of treatment of
these patients. Furthermore, we assessed differences of MT
use dependent on regional population density and fre-
quency of treatment in all German treatment sites. Our
findings may help to improve nation-wide acute stroke
care including MT.
Methods
Analyses were based upon the statistical evaluation of
the German Diagnosis-Related Groups (G-DRG) data
from 2010 to 2016 (DRG-statistic, Federal Statistical
Office, www.destatis.de) as well as the mandatory struc-
tured quality reports of hospitals (according to §137, 3;
Social Code Book V of Germany) from the year 2016,
enabling the calculation of IVT and MT rates in each
hospital and the number of ischemic stroke patients
treated in each hospital1. We extracted all cases with the
main ICD-10 code I63 (ischemic stroke) and calculated
population based incidence, mean age and gender. Cases
being transferred once or multiple times from one hos-
pital to another either for acute stroke therapy and/or
early rehabilitation were censored appropriately to avoid
double and multiple coding (exclusion of “discharge key
06”). Therefore, first ever as well as recurrent strokes
were included with the exception of early recurrences
that occurred during the ongoing hospital treatment
phase for the first incidence. In a cross over analysis, the
associated stroke recanalization therapy was categorized
by using the corresponding Operating and Procedure
Key for systemic thrombolysis (OPS code 8–020.8) and
mechanical thrombectomy (OPS 8–836.80). Estimation
of bridging-IVT rate was done by cross over analysis of
lead-DRGs coding for MT-procedures.
In a first step, data were analyzed based upon the pa-
tients’ place of residence. Regional analyses were done
by data aggregation considering the 413 German admin-
istrative districts and cities. To avoid bias, we excluded
all cases of foreign or unknown place of residence from
regional statistics.
In a second step, analysing the data from the structured
quality reports of the hospitals2, we calculated the number
of IVT and MT cases in each hospital and the number of
acute ischemic stroke patients treated in each hospital.
Hospitals without neurological departments coding MT
procedures were excluded. This was done due to the as-
sumption that these patients were either treated by inter-
ventionalists other than (neuro-) radiologists in cooperation
with neurologists, or were most probably coded twice, i.e.
in a neurointerventional center and afterwards in a geriatric
(or neurological) early rehabilitation clinic. In such ascenario, case assignment would be allocated to the hospital
with the geriatric/rehabilitation department.
We stratified hospitals by number of MTs performed
per year into the following categories: 1–9, 10–34, 35–49,
50–99, 100–199, > 200. These categories were chosen for
the following reasons:
• Seldom MT treatments and possible false entries
(1–9): with less than one treatment per month no regu-
lar experience can be presumed.
• Occasional MT treatments (10–34 and 35–49):
with less than one treatment per week / every two weeks
only occasional experience can be presumed according
to undergoing discussions on different minimal require-
ments for procedures per year.
• Regular MT treatments (50–99): with more than 1
treatment per week, a regular experience in interven-
tional stroke treatment can be presumed.
• Frequent MT treatments (100–199): with 2 to 4
treatments per week, a good experience of several neu-
rointerventionalists can be presumed and the center can
be regarded as a training center.
• High volume MT treatments (> 200): with more
than 4 treatments per week, a very good experience can
be presumed and the neuro-interventionalists can be
regarded as experts.
We used the Eurostat definition to stratify the 413 Ger-
man administrative districts and cities into densely popu-
lated areas (cities) with a population density over 500
inhabitants per km2 and a minimum population of 50.000
inhabitants, intermediate density areas with a population
density between 500 and 100 inhabitants per km2, and
thinly populated (rural) areas with a population density
below 100 inhabitants per km2.
We searched PubMed for studies in English language
up to September 30, 2018 using the terms “ischemic
stroke” AND “mechanical thrombectomy” OR “mechan-
ical recanalization” OR “intraarterial recanalization” OR
“thromboaspiration” to identify studies investigating na-
tionwide coverage, regional differences and temporal de-
velopment of mechanical thrombectomy (MT) in acute
ischemic stroke patients after the introduction of mod-
ern MT systems (stent retrievers and thromboaspiration
systems).
For descriptive analyses, results are reported as abso-
lute numbers and mean. Statistical comparison of
groups was performed with the Mann-Whitney-U-test.
A p value of < 0·05 was considered significant. All ana-
lyses were performed with Microsoft Excel and IBM
SPSS version 21.
Results
The administrative hospital data from all German acute
care hospitals showed an absolute increase of 10.2% for
the total number of ischemic strokes (ICD I63) from
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patients with ischemic stroke was 75 years and remained
stable over this period, with female stroke patients being
significantly older (Table 1 and Fig. 1).
The nationwide rate of IVT continuously increased from
8.9% in 2010 to 14.9% in 2016 (Table 1). The IVT rate
showed a high variation between German cities and dis-
tricts in all years analyzed (2016: 2.4–28.0%; Table 1). The
mean age of acute stroke patients receiving IVT slightly
increased from 73.3 years in 2010 to 74.4 years in 2016
caused by a doubling of the IVT rate in patients over 80
years of age (from 7.0% in 2010 to 14.4% in 2016, Table 1).
The overall rate of MT in ischemic stroke patients in
Germany increased from 0.8% in 2010 to 4.7% in 2016,
with a wide regional range, according to place of resi-
dence, between 0 and 11.2% in 2016 (Table 1 and Fig. 2).
From 2010 to 2012, the MT rate increased steadily, with a
slow-down in 2013 and 2014 (after publication of the first
three neutral randomized MT trials in spring 2013), and
increased sharply again from 2014 to 2016 (after publica-
tion of the positive randomized MT trials) (Table 1 and
Fig. 2). In 2016, the mean MT rate in the 20 cities/districts
with the highest MT rates was 8.4% (range 7.2 to 11.2%),
and the mean MT rate in the 20 cities/districts with the
lowest MT rates was 1.0% (range 0 to 1.3%). There was
only one small district, in which no ischemic stroke pa-
tient received MT in 2016.
The rate of IVT in combination with MT (“bridging
approach”) declined from 75% in 2010 to 51% in 2016.
The mean age of patients receiving MT increased from
67.8 years in 2010 to 73.3 years in 2016 and was compar-
able to the mean age of stroke patients treated with IVT
in 2016 (74.4 years; Table 1 and Fig. 1).
The temporal evolution of MT rates dependent on the
population density is shown in Fig. 3. MT rates in urban
(> 500 inhabitants/km2) and rural (< 100 inhabitants/Table 1 Rates of ischemic stroke, intravenous thrombolysis and mec
2010 2011 2012
Ischemic strokes (ICD I63), n 206.688 209.976 214.157
Age, mean 75.1 75.1 75.0
Sex, male (%) 49.0% 49.3% 49.9%
IVT overall, n (%) 18.362 (8.9%) 21.381 (10.2%) 24.426 (11.4
Age, mean 73.0 73.5 73.7
IVT rate < 80 years, % 10.0% 11.1% 12.2%
IVT rate≥ 80 years, % 7.0% 8.6% 10.1%
MT overall, n (%) 1.662 (0.8%) 3.061 (1.5%) 4.505 (2.1%
Age, mean 67.8 69.0 69.9
MT rate < 80 years, % 1.1% 1.8% 2.6%
MT rate≥ 80 years, % 0.4% 0.8% 1.2%
Percentage values are based on all patients with ICD code I63
ICD indicates International Statistical Classification of Diseases and Related Health Pkm2) areas did not statistically differ in 2010(0.76% vs.
0.83%, p = 0.795). Thereafter, MT rates in urban settings
were significantly more frequent(2012: 2.0% vs. 1.3%,
p = 0·001; 2014: 2.9% vs. 1.8%, p < 0·001; 2016: 5.4%
vs. 3.8%, p < 0.001.
Figure 4 depicts the temporal and regional evolution
of the MT rate in all 413 German cities and districts
from 2010 to 2016. Figure 4(a) illustrates the MT rates
according to place of residence and Fig. 4(b) illustrates
the numbers according to place of treatment.
The number of hospitals coding MT without having
a neurological department according to the available
structured quality reports was 16 in 2010 and 31 in
2016 with 34 procedures in 2010 and 46 procedures
in 2016 accounting for 2.1 and 0.4%, respectively.
These hospitals were excluded in the following results
as mentioned above. Detailed results of hospitals with
different MT rates can be seen in Table 2 and Fig. 5.
62% of all hospitals coding MT treated fewer than 50
procedures in 2016 accounting for 20% of all proce-
dures. The number of centers with regular and fre-
quent MT procedures (50–99 / 100–199 MT per
year) increased considerably with procedure numbers
accounting for 33% / 0% in 2010 and for 24% / 33%
in 2016, respectively. There were 9 high volume neu-
rointerventional centers (> 200 MT/year) in 2016 with
a total of 2297 MT procedures performed, accounting
for 22% of all MT procedures.
Discussion
This nation-wide analysis indicates a direct impact of the
published randomized MT trials on the overall MT rate,
with a slowing increase after the first three neutral ran-
domized MT trails (IMS III, SYNTHESIS, MR RESCUE)
in 2013, [2–4] and a prompt and strong increase after
publication of the positive randomized MT trials in 2014hanical thrombectomy from 2010 to 2016 in Germany
2013 2014 2015 2016
216.535 218.371 222.220 227.687
75.0 75.0 75.0 75.0
50.4% 50.7% 51.5% 51.8%
%) 26.764 (12.4%) 28.447 (13.0%) 30.589 (13.8%) 33.916 (14.9%)
73.9 74.1 74.4 74.4
13.0% 13.5% 14.1% 15.2%
11.2% 12.2% 13.1% 14.4%
) 5.141 (2.4%) 5.526 (2.5%) 7.840 (3.5%) 10.692 (4.7%)
70.2 70.6 71.9 73.3
2.9% 3.1% 4.0% 5.1%
1.4% 1.6% 2.6% 4.1%
roblems, IVT intravenous thrombolysis, MT mechanical thrombectomy
Fig. 1 Mean age of all patients with ischemic stroke (black), treated with intravenous (grey) thrombolysis and mechanical thrombectomy (white)
in Germany from 2010 to 2016
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SWIFT-PRIME, REVASCAT) [6–9]. On the other hand,
almost 20,000 acute stroke patients were treated with MT
from 2010 till the end of 2014 without clear evidence from
randomized trials. This high patient number shows the
potential for recruitment into randomized controlled MT
trials if reimbursement had been linked to study participa-
tion like in the Netherlands with MR CLEAN.
The mean age of patients receiving MT increased
after 2015 mainly due to a higher proportion of octo-
genarians, almost reaching the mean age of patients
treated with intravenous rt-PA alone.Fig. 2 Temporal evolution of mechanical thrombectomy rates in Germany
per year)Not unexpectedly, the MT rate according to place of
residence varied substantially in 2016 between 0% in one
small rural area and 11.2% in a larger metropolitan area.
Acute ischemic stroke patients living in urban areas had
a significantly higher chance to receive MT from 2012
onwards compared to patients living in rural areas. This
emphasizes the need for developing regional-specific
neurovascular network solutions. Currently, different ap-
proaches are debated for patients with LVO: “drip and
ship” with primary transportation to the closest stroke unit,
standard diagnostics, and secondary transportation to an
interventional centre with bridging IVT if indicated; orbetween 2010 and 2016 (Slope is given as absolute percentage points
Fig. 3 Rates of mechanical thrombectomy performed in Germany, in urban (grey) and rural (white) areas from 2010 to 2016
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verely affected stroke patients to a neurointerventional
centre. Patients receiving MT under the latter condition
have better functional outcome mainly due to a signifi-
cantly shorter delay between first brain imaging and groin
puncture [17, 18] since “time is brain” is also valid in stroke
patients treated with MT [19]. On the other hand, “drip
and ship” reduces the time delay to standard IVT therapyFig. 4 a Maps of temporal and regional evolution of mechanical thrombectom
of the patients. b Maps of temporal and regional evolution of mechanical thro
treatment in hospitaland stroke unit treatment in the remaining predominant
group of patients without indication for MT. A consider-
able amount of time (namely the time interval between ad-
mission at the interventional centre to groin puncture)
could be saved in stroke patients secondarily referred for
MT in the metropolitan area of the Neurovascular Net
Ruhr due to prior notification about eligible patients and
standardized operating procedures [17, 20]. In somey rates in Germany from 2010 to 2016 according to places of residence
mbectomy rates in Germany from 2010 to 2016 according to places of
Table 2 German hospitals with a dedicated department of Neurology encoding mechanical thrombectomy (MT, OPS 8–836.80) from
2010 to 2016 categorized by numbers of MT performed per hospital and illustration of numbers of MT performed in the categories
Numbers of MT
per hospital
Numbers of hospitals
and procedures in 2010
Numbers of hospitals
and procedures in 2012
Numbers of hospitals
and procedures in 2014
Numbers of hospitals
and procedures in 2016
1–9 40 /143 52 /230 55 / 182 49 /148
10–34 36 / 638 48 / 1040 49 / 992 53 / 1168
35–49 7 / 282 14 / 568 19 / 804 20 / 855
50–99 8 / 533 26 / 1768 32 / 2304 35 / 2537
100–149 0 / 0 3 / 335 5 / 597 22 / 2666
150–199 0 / 0 0 / 0 0 / 0 5 / 847
200> 0 / 0 2 / 513 2 / 558 9 / 2297
Sum 91 / 1596 145 / 4454 162 / 5437 193 / 10,518
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interventional stroke team resorts to the primary stroke
centre, may utilize the advantages of time sensitive initi-
ation of thrombolysis with simultaneous on-site prepar-
ation for interventional therapy [21].
Our analysis of the latest available data for Germany
in 2016 demonstrate that only 1% of all MT were per-
formed in hospitals with less than 10 MT procedures
per year. The number of MT procedures performed in
hospitals with only occasional treatment (up to 50 MT/
year) increased only moderately over the past 6 years,
while centers with regular, frequent and highly frequent
MT procedures increased considerably from 2010 to
2016. Overall, 80% of all MT procedures in 2016 were
performed in neuro-interventional centers with at least
≥50 MT/year which is in our opinion an adequate
number to provide sufficient technical and organi
zational expertise along with 24/7 MT service to treatFig. 5 Proportion of patients being treated in different centers, classified acdirectly admitted and secondarily referred stroke
patients with LVO.
The three departments with the most procedures in
2016 performed 386, 362, and 234 MTs, respectively. On
the basis of theoretical considerations, 5–15% of all
stroke patients or 14-41 per 100.000 inhabitants3 can be
expected to be eligible for MT in Germany [14–16].
Considering an average value of 28 per 100.000 or 10%
of all strokes, the three hospitals with the most MT pro-
cedures in 2016 should therefore have a population
coverage of approx. 1.38mio, 1.29mio, and 840.000 in-
habitants, respectively. However, center no.1 is located
in a metropolitan area in a city of approx. 583,000 in-
habitants with another treatment center in the city and
another 6 regular, frequent, or high volume centers in an
ambit of 50 km. Center no.2 is located in a city of
approx. 628,000 inhabitants with another frequent treat-
ment center some 15 km away, and center no.3 iscording to the number of MT performed per year
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304.000 inhabitants only 20 km away without a regular
treatment center.
These examples demonstrate the inhomogeneous in-
frastructure neurointerventional centers have to deal
with. Three major aspects may influence strategic orien-
tation of hospitals with (potential) interventional depart-
ments. A) local and regional patient care; B) adequate
treatment rates to keep up quality standards; C) poten-
tial financial incentives and reputation. Stroke unit treat-
ment compensation is the sound basis of stroke
medicine in Germany. Within the DRG system, the
compensation of a stroke patient increases by approx.
2.3 fold if MT is performed on top of systemic thromb-
olysis and stroke unit treatment of more than 72 h. We
assume that about 13% of the absolute amount of com-
pensation for stroke treatment (I63) in 2016 has been
spent for MT compensation4. It stands to reason that
hospital managers might not want to miss the potential
financial amenities of interventional stroke treatment.
Hence, these numbers also imply that financial consider-
ations are to be considered as one incentive to offer MT.
At the same time, the definitions of structural require-
ments to enable rapid and 24/7 access for MT for acute
stroke patients with LVO as well as minimal treatment
numbers for neuro-interventionalists constitute feasible
instruments to foster standards of quality. To tackle this
balancing act, it is the responsibility of the respective
professional societies to guide infrastructural develop-
ments in order to prevent falsely driven decisions for
interventional centers in the whole range of treatment
frequencies. A good coverage of high quality stroke care
rather than financial interests must be our number one
incentive.
The decreasing percentage of bridging IVT observed
over the years is most likely not primarily caused by a
paradigm shift from “drip and ship” to “direct to mother-
ship”, rather than by an increasing number of MT
procedures performed without bridging-IVT in larger
neuro-interventional centers and/or due to consisting
contraindications for IVT, i.e. unknown time window or
wake up strokes, known malignancies, recent operations,
etc [22, 23]. It has to be pointed out, that direct MT with-
out bridging IVT performed in IVT-eligible patients dir-
ectly admitted to neuro-interventional centers is still a
matter of debate and that prospective randomized trial ad-
dressing this question are under way (SWIFT DIRECT,
MR CLEAN NO IV).
Our data refer to the overall number of a main diagno-
sis of ischemic stroke (ICD I63) irrespective of, e.g.,
symptom onset time, clinical details or basis of indica-
tion, such as vascular occlusion status or symptom
severity. However, these administrative data have high
quality and accuracy because registration of all ischemicstroke cases and acute treatment procedures is a pre-
requisite to get financial compensation, and the coding
of operating and procedure keys for MT and IVT are
closely controlled by medical services of the health in-
surances. The system itself assures that one IVT or MT
procedure refers only to one acute ischemic stroke pa-
tient, even if the patient has been transferred to a second
hospital for MT. Furthermore, no change in coding stan-
dards occurred in the analyzed time period. Thus, in
contrast to observational registries, our data are very
robust for Germany with a very low risk of missing pa-
tients, double coding of procedures, resulting in high
validity and consistency.
The observed increase of patients with the main diagno-
sis of ischemic stroke over time can be attributed to differ-
ent aspects. It is likely that patients with stroke are now
more often adequately diagnosed due to the increasing
number of stroke units over the years and awareness for
stroke. Secondly, both first and recurrent ischemic strokes
are included in our data, which might has contributed to
the observed overall increase of the code I63 in an aging
population. Finally, there is the possibility that reimburse-
ment of the diagnosis ischemic stroke and of the related
MT procedure resulted in a higher amount of coding over
time and as a consequence in an increase of the raw ische-
mic stroke rate. Stroke rates from our study cannot be
compared with different ICD 10 data used for causes of
death in the Global Burden of Diseases Report [1].
To date, there is only scarce data on national availabil-
ity of MT in acute ischemic stroke patients. Hassan and
co-workers analysed the utilization of MT in the US
from 2004 to 2007 (so called “post-MERCI” period) and
from 2008 to 2009 (so called “post-Penumbra” period)
and reported an overall endovascular treatment rate of
0.1% in 2004 and 0.6% in 2009 with a MT rate of only
0.2% in patients aged ≥85 years [24]. A more recent ana-
lysis from the National Inpatient Sample in the US
reported an increase of MT use in stroke patients from
0.6% in 2008 to 1.1% in 2012 [25]. In a prospective
Korean hospital based registry with up to 14 participat-
ing hospitals (mostly university hospitals in metropolitan
areas) over the time period from April 2008 to Novem-
ber 2013, a total of 3517 of 27.851 (12.7%) stroke pa-
tients received any acute recanalization treatment, i.e.
IVT and / or interventional therapy, and 1269 (36.1%) of
the 3517 patients were treated with endovascular proce-
dures alone or in combination with IVT (4.5% of all in-
cluded cases) [26]. More recently, a survey from national
scientific societies and stroke experts in 44 European
countries estimated that 7.3% (95% CI 5.4–9.1%) of inci-
dent ischemic stroke patients received IVT in 2015 or
2016, and 1.9% (95%CI 1.3–2.5%) received MT in 2016
[27]. The estimations used in this analysis were mostly
based on data from national stroke registries. An annual
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estimated for Germany, which is in a similar range com-
pared to our administrative data [27].
To our knowledge, the hospital-based analysis presented
here is the first serial nationwide coverage of actual MT
treatment rates and suggest a widespread uptake of this
new treatment in Germany. Population-based data is still
lacking.
Conclusion
The nation-wide rate of IVT in acute ischemic stroke in
Germany has increased over the past years and an expo-
nential increase of MT procedures was detected after pub-
lication of the positive study results. Mean age of patients
undergoing MT has continuously increased and has re-
cently almost reached the mean age of patients undergoing
IVT. Therefore, MT can be regarded as an established
standard therapy in some (mostly urban) regions of
Germany. However, the wide range of both the IVT and
MT rates in German ischemic stroke patients indicates the
need for further improvement of access to acute recanali-
zation therapies in many, mainly rural regions. Infrastruc-
tural improvement should focus both on access to
neuro-interventional centers with adequate expertise, es-
tablishment of reliable standard operating procedures for
transfer for MT, as well as strengthening the competence
of local stroke units for standard care including IVT and
rapid and reliable recognition of MT candidates with stan-
dardized brain and vessel imaging.
There is a trend towards medium and high volume
treatment centers in Germany in 2016 with most MT
procedures (80%) performed in centers with ≥50 MT
procedures per year in 2016. It is expected in the near
future that stroke societies will recommend that at least
35 to 50 MT procedures should be performed in a
neuro-interventional center per year for quality reasons.
Endnotes
1For financial compensation in Germany, all in-hospital
cases are encoded by International Statistical Classification
of Diseases and Related Health Problems 10th revision,
German modification (ICD-10-GM) and relevant operating
and procedure keys (OPS codes). In the analyzed time
period there was no change in the German coding system
or a revision of the ICD version. Data analyzed in this
manuscript are publicly accessible in general. However,
the original data of the hospitals’ quality reports subject to
§137 Abs. 3, 1 No. 4 SGB V are not directly accessible. In
order to analyze the data complexity as done in this
manuscript, the whole data base has to be obtained as
extensible markup-language-version and then to be
readouted by a specific program. A complete and un-
altered subscription of the quality reports is available with
the Gemeinsamer Bundesausschuss (G-BA, Federal JointCommittee): https://www.g-ba.de/institution/themensch-
werpunkte/qualitaetssicherung/qualitaetsdaten/qualitaets-
bericht/xml-daten/). Likewise, DRG raw data by Destatis
in the data complexity analyzed here are not publicly vis-
ible and have to be obtained as paid service for users as
either zip- or access-data file (https://www.destatis.de/DE/
Service/Kontakt/Kontakt.html).
2Structured Quality Reports of the hospitals according
to §137 3.1 No. 4 SGB V (reported years 2010–2016),
XML-version, G-BA
3Assuming a stroke incidence of 276 per 100.000 with
227.687 strokes (ICD I63) in Germany in 2016 (see above)
and a population of 82.500.000 inhabitants (https://www.des
tatis.de/DE/PresseService/Presse/Pressemitteilungen/2018/01/
PD18_019_12411.html)
4Even though difficult to calculate for methodological
reasons, we calculated real costs of about 1.6 bn Euro
for all coded I63 cases with about 211 mio for all cases
comprising MT (OPS 8–836.80).
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need not apply to secondary data analyses, if all the data protection provisions
on pseudo-anonymization of all personal data are fulfilled ... and no link to
primary data is intended." Datasets used for this analysis were completely
anonymized data provided by the German federal statistical office (DRG-statistic,
www.destatis.de) in compliance with the German data protection regulations
and this also applied to the evaluation of the quality reports. All requirements
Weber et al. Neurological Research and Practice             (2019) 1:4 Page 9 of 9from the general conditions for the use of the quality reports of the hospitals in
machine-readable form were observed (www.g-ba.de). Since there was no
access to any individualized patient data whatsoever, no informed patient
consent or ethical approval was needed for this study.
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